MAPT and early-onset autosomal dominant Alzheimer disease: In the Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD) study, outcomes include adverse events, cellular senescence blood markers, Clinical Dementia Rating - Sum of Boxes (CDR-sb), Alzheimer’s Disease Assessment Scale - Cognitive Subscale (ADAS-cog), and tau positron emission tomography (PET).